Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Anti-CYP4Z1 autoantibodies detected in breast cancer patients

Cellular & Molecular Immunology volume 14, pages 572–574 (2017)Cite this article

Autoantibodies (aAbs) are generated by the immune system in response to a number of stimuli, one of which is believed to be aberrant protein targeting to the plasma surface. In this study, the presence of human cytochrome P450 enzyme CYP4Z1 on the outer surface of the plasma membrane of MCF-7 breast cancer cells is demonstrated by immunofluorescence. Moreover, anti-CYP4Z1 aAbs could clearly be detected in breast cancer patient sera by both immunoprecipitation and western blot analysis, while weak or no signals were obtained when testing controls. In an indirect CYP4Z1 ELISA, reactive aAb titers were significantly higher in breast cancer patient samples than in controls. High-resolution epitope mapping of five breast cancer patient sera revealed strong recognition of an epitope that is located on the surface of the enzyme.

Cytochrome P450 enzymes (CYPs or P450s) are a superfamily of heme-containing monooxygenases that are widely distributed in every domain of life. Many of the 57 human CYP enzymes are involved in the bioconversion of xenobiotics, which includes hepatic drug metabolism and the bioactivation of chemical carcinogens, but some family members have their predominant role in the biosynthesis of physiologically important compounds such as steroids and fatty acids. However, these two groups are not strictly separated from each other and overlaps exist; for instance, some CYPs involved in steroid hydroxylation are less specific than once thought and can also oxidize foreign compounds with related structures. Human CYPs are membrane-bound enzymes that are either located on the cytoplasmic side of the endoplasmic reticulum or on the matrix side of the inner mitochondrial membrane; for their activity they typically depend on specific electron transfer proteins that are co-localized with them.1 Interestingly, several studies have demonstrated that some microsomal CYPs (such as CYP1A2, CYP2D6 and CYP2E1) as well as cytochrome P450 reductase are transported through secretory vesicles from the endoplasmic reticulum to the outer surface of rodent or human hepatocytes where they face the extracellular space and are catalytically active. Such plasma membrane-localized CYPs are probably one cause for the emergence of anti-CYP aAbs found in patients with a number of liver diseases as well as in patients with some endocrine or autoimmune disorders; for instance, CYP21A2 is the major adrenal cortex autoantigen in idiopathic Addison’s disease,2 and CYP2D6 is the molecular target of anti-LKM1 (liver kidney microsomal type 1) Abs, which are detectable in type II autoimmune hepatitis and in some patients with HCV hepatitis.3, 4 All CYPs for which plasma membrane localization has been shown are also known antigens. However, anti-CYP aAbs in cancer patients have not been reported to date, despite the fact that a number of human CYPs (including members of the families CYP1-4 as well as CYP19A1) are known to be overexpressed in various types of malignancies, such as breast, colorectal, lung or ovarian cancer. One of these enzymes is CYP4Z1, which is selectively expressed in mammary tissue and almost undetectable in other healthy human tissues, but displays a strong overexpression in breast cancer and ovarian cancer cells.5, 6 We have previously shown that CYP4Z1 catalyzes the monohydroxylation of lauric and myristic acid, although it is not known whether this activity is its major physiological function.7

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Hannemann F, Bichet A, Ewen KM, Bernhardt R . Cytochrome P450 systems-biological variations of electron transport chains. Biochim Biophys Acta 2007; 1770: 330–344.

    Article  CAS  Google Scholar 

  2. Winqvist O, Karlsson FA, Kampe O . 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 1992; 339: 1559–1562.

    Article  CAS  Google Scholar 

  3. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D . Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008; 14: 3374–3387.

    Article  CAS  Google Scholar 

  4. Dalekos GN, Zachou K, Liaskos C, Gatselis N . Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Int Med 2002; 13: 293–303.

    Article  CAS  Google Scholar 

  5. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 2005; 11: 7369–7375.

    Article  CAS  Google Scholar 

  6. Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, Schmitz M et al. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res 2004; 64: 2357–2364.

    Article  CAS  Google Scholar 

  7. Zöllner A, Dragan CA, Pistorius D, Muller R, Bode HB, Peters FT et al. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol Chem 2009; 390: 313–317.

    Article  Google Scholar 

  8. Yang X, Hutter M, Goh WW, Bureik M . CYP4Z1—A human cytochrome P450 enzyme that might hold the key to curing breast cancer. Curr Pharm Des; e-pub ahead of print 7 February 2017; doi:10.2174/1381612823666170207150156.

  9. Stadler V, Felgenhauer T, Beyer M, Fernandez S, Leibe K, Guttler S et al. Combinatorial synthesis of peptide arrays with a laser printer. Angew Chem Int Ed Engl 2008; 47: 7132–7135.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Feng Yu-Mei from the Department of Biochemistry and Molecular Biology at Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) for providing cancer patient sera and to Zhang Weiying from the Institute of Molecular Biology at Nankai University (Tianjin, China) for providing MCF-7 cells.

Author information

Authors and Affiliations

  1. School of Pharmaceutical Science and Technology, Health Science Platform, Tianjin University, Tianjin, 300072, China

    Venkatrao Nunna, Nasir Jalal & Matthias Bureik

Authors
  1. Venkatrao Nunna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nasir Jalal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Bureik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Bureik.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nunna, V., Jalal, N. & Bureik, M. Anti-CYP4Z1 autoantibodies detected in breast cancer patients. Cell Mol Immunol 14, 572–574 (2017). https://doi.org/10.1038/cmi.2017.21

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cmi.2017.21

This article is cited by

Search

Advanced search

Quick links